Kaleido Biosciences Performance
| KLDODelisted Stock | USD 0.01 0.00 0.00% |
The company secures a Beta (Market Risk) of 95.0, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Kaleido Biosciences will likely underperform. Kaleido Biosciences right now secures a risk of 0.0%. Please verify Kaleido Biosciences variance, potential upside, as well as the relationship between the Potential Upside and day typical price , to decide if Kaleido Biosciences will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kaleido Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy fundamental indicators, Kaleido Biosciences is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 48.4 M | |
| Total Cashflows From Investing Activities | -691 K |
Kaleido |
Kaleido Biosciences Relative Risk vs. Return Landscape
If you would invest 1.00 in Kaleido Biosciences on August 31, 2024 and sell it today you would earn a total of 0.00 from holding Kaleido Biosciences or generate 0.0% return on investment over 90 days. Kaleido Biosciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Kaleido, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kaleido Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kaleido Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Kaleido Biosciences, and traders can use it to determine the average amount a Kaleido Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| KLDO |
Based on monthly moving average Kaleido Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kaleido Biosciences by adding Kaleido Biosciences to a well-diversified portfolio.
Kaleido Biosciences Fundamentals Growth
Kaleido Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Kaleido Biosciences, and Kaleido Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kaleido Pink Sheet performance.
| Return On Equity | -5.81 | ||||
| Return On Asset | -1.0 | ||||
| Operating Margin | (79.28) % | ||||
| Current Valuation | (16.73 M) | ||||
| Shares Outstanding | 42.62 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 0 X | ||||
| Price To Sales | 0.04 X | ||||
| Revenue | 1.1 M | ||||
| EBITDA | (85.09 M) | ||||
| Cash And Equivalents | 38.47 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 5.55 M | ||||
| Debt To Equity | 2.04 % | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | (77.09 M) | ||||
| Earnings Per Share | (2.16) X | ||||
| Total Asset | 50.14 M | ||||
| Retained Earnings | (197.63 M) | ||||
| Current Asset | 72.93 M | ||||
| Current Liabilities | 10.39 M | ||||
About Kaleido Biosciences Performance
By examining Kaleido Biosciences' fundamental ratios, stakeholders can obtain critical insights into Kaleido Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Kaleido Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 76 people.Things to note about Kaleido Biosciences performance evaluation
Checking the ongoing alerts about Kaleido Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Kaleido Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kaleido Biosciences is not yet fully synchronised with the market data | |
| Kaleido Biosciences has some characteristics of a very speculative penny stock | |
| Kaleido Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.1 M. Net Loss for the year was (90.29 M) with loss before overhead, payroll, taxes, and interest of (66.7 M). | |
| Kaleido Biosciences currently holds about 38.47 M in cash with (77.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Kaleido Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kaleido Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Kaleido Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kaleido Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kaleido Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kaleido Biosciences' pink sheet. These opinions can provide insight into Kaleido Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Kaleido Pink Sheet
If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| CEOs Directory Screen CEOs from public companies around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |